Banner



PDX model details

PDX ID 167.2M
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
27
Average PDX Generation Time (days +/- SEM) 48 ± 2
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304; 33620092
Markers 167.2M
AR Y
PSA Y
PSMA Y
NE N
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
167.2M APC -1.656 0.635 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M AR 1.581 2.991 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M ARID2 0.564 2.956 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M CCND1 1.130 4.377 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M CHD7 0.631 3.097 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M KMT2A 0.740 3.341 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M KMT2D 0.564 2.956 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M MYC 0.631 3.097 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M PIK3CA 1.283 4.868 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M PIK3CB 1.283 4.868 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M PTEN -1.688 0.621 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M PTEN -4.339 0.099 Homdel MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M SPEN 0.977 3.935 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
167.2M ZFHX3 0.617 3.066 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19

Clinical Information

Sample Number 167.2M
Sample Site Spine
Sample source Surgery
Pathology Tumour Diagnosis Adenocarcinoma
Gleason Score 9
Primary Gleason Score 4
Secondary Gleason Score 5
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel

Patient Information

Patient Number 167
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 5.2
Consent to share data

Patient Tumour Collection (Current Model)
Tumour sample ID 167.2M
Patient Age (binned in 5 year age groups) 55-59
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
167.2M TP53 265 0.98 Missense variant '7/11 . 32 Uncertain significance Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
167.2M APC 106 0.88 Frameshift variant '16/16 . 34 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
167.2M DCLK3 280 0.66 Missense variant '4/5 . 25.3 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
167.2M PRLR 746 0.49 Missense variant '10/10 0.0008899 23.2 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500